Inhaled Budesonide for Prevention of Acute Mountain Sickness: A Single Center, Randomized, Double-Blind, Controlled, Prospective Trial.

Inhaled Budesonide for Prevention of Acute Mountain Sickness- A Single center, Radomized, Double-Blind,Controlled, Prospective Trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-12002748

Enrollment

Unknown

Registered

2012-12-05

Start date

2012-06-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute mountain sickness

Interventions

Procaterol (Meptin):Procaterol (Meptin) 25ug, twice/daily

Inhaled Budesonide:Inhaled Budesonide 200ug twice per day

Inhaled Budesonide/Formoterol:Inhaled Budesonide/Formoterol 160ug/4.5ug twice per day

placebo:Vitamin B1 10mg twice per day

Eligibility

Sex/Gender

Male

Age

17 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy adults rushing into plateau, with normal hepatorenal function, and without organic disease, aged from 17 to 60; 2. Patients diagnosed by AMS criteria.

Exclusion criteria

Exclusion criteria: High altitude exposure history within past 12 months; Patients with psychological or neurological disorder. Patients with bad comp1iance.

Design outcomes

Primary

Measure	Time frame
Lake Louise Score standard;Oxygen saturation;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;pulmonary function test;pulmonary function tests;	—

Countries

China

Contacts

Public ContactHuang Lan

huanglan260@yahoo.com.cn+86 13808398102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026